Command Palette

Search for a command to run...

ONYX

41.4-0.24%
Market Cap
₹0.00 Cr
Stock P/E
0.00
ROCE
0.00%
ROE
0.00%
Book Value
₹0.00

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Institution
Public
Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

Onyx Biotec Ltd. stands out in the peer comparison, primarily due to its lack of financial metrics, which positions it differently from its peers. Companies like Sun Pharmaceutical and Dr. Reddy's Laboratories demonstrate strong profitability and growth metrics, while Divi's Laboratories shows some weaknesses in growth despite solid margins. Overall, while Onyx Biotec lacks operational performance indicators, peers provide a clearer picture of sector dynamics with distinct leaders and laggards.

Key Points
  • Onyx Biotec Ltd. has no revenue, EPS, or profitability metrics reported, making direct comparison challenging.
  • Sun Pharmaceutical Industries Ltd. leads in profitability with a ROE of 16.13% and EPS growth of 45.55.
  • Cipla Ltd. displays strong revenue growth (YoY 13.28%) and a low PE ratio (23.73), making it a solid value option.
  • Divi's Laboratories Ltd. shows high valuation metrics but lacks consistent growth, highlighting potential risk.
  • Dr. Reddy's Laboratories Ltd. ranks well in terms of profitability and growth, making it a strong peer.
Top Performers
Cipla Ltd.

Strong revenue growth (YoY 13.28%) and low PE ratio (23.73), indicating good value and profitability.

Sun Pharmaceutical Industries Ltd.

Leads in profitability with a high ROE of 16.13% and EPS growth of 45.55%.

Dr. Reddy's Laboratories Ltd.

High profitability metrics and solid growth trajectory with an EPS increase of 68.07%.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.